FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Zhang Jack Y. 2. Issuer Name and Ticker or Trading Symbol Amphastar Pharmaceuticals, Inc. [ AMPH ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO & Chief Scientific Officer
(Last)          (First)          (Middle)
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
3/15/2022
(Street)
RANCHO CUCAMONGA, CA 91730
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  3/15/2022    A    76914 (1) A $0.00  2397782  D   
Common Stock  3/15/2022    F    14759 (2) D $34.74  2383023  D   
Common Stock  3/15/2022    A    32412 (1) A $0.00  1520783  I  See footnote (3)
Common Stock  3/15/2022    F    4786 (2) D $34.74  1515997  I  See footnote (3)
Common Stock                 6827679  I  See footnote (4)
Common Stock                 5000  I  See footnote (5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)  $34.74  3/15/2022    A     177461       (6) 3/15/2032  Common Stock  177461  $0  177461  D   
Employee Stock Option (right to buy)  $34.74  3/15/2022    A     74784       (6) 3/15/2032  Common Stock  74784  $0  74784  I  See footnote (3)

Explanation of Responses:
(1)  The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on March 15, 2023.
(2)  The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.
(3)  The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
(4)  The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.
(5)  The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
(6)  The shares subject to the option vest in four equal annual installments beginning on March 15, 2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Zhang Jack Y.
C/O AMPHASTAR PHARMACEUTICALS, INC.
11570 6TH STREET
RANCHO CUCAMONGA, CA 91730
X X CEO & Chief Scientific Officer
Luo Mary Z.
C/O AMPHASTAR PHARMACEUTICALS, INC.
11570 6TH STREET
RANCHO CUCAMONGA, CA 91730
X X CEO & Chief Scientific Officer

Signatures
/s/ Eva Wen, by power of attorney for Jack Y. Zhang 3/17/2022
**Signature of Reporting Person Date
/s/ Eva Wen, by power of attorney for Mary Z. Luo 3/17/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Amphastar Pharmaceuticals Charts.
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Amphastar Pharmaceuticals Charts.